Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05964465 · ClinicalTrials.gov registry record · Phase 4

Mechanisms of Smell Improvement With Dupilumab.

A Phase 4 study of Chronic Rhinosinusitis With Nasal Polyps, sponsored by Medical University of South Carolina.

Completed
Registry status
Phase 4
Development phase
60
Enrollment target
2
Study locations

NCT05964465 is a Phase 4 study of Chronic Rhinosinusitis With Nasal Polyps that has completed, run by Medical University of South Carolina. The registered enrollment target is 60 participants, below the 137-participant average among 11 other Chronic Rhinosinusitis With Nasal Polyps trials with a reported enrollment target (56% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05964465, a Phase 4 study of Chronic Rhinosinusitis With Nasal Polyps, has completed, sponsored by Medical University of South Carolina.

COMPLETED
Registry status
Phase 4
Development phase
60 participants
Enrollment target
2
Study locations

Study Summary

This study seeks to explore the mechanism through which dupilumab improves olfactory cleft inflammation in patients with chronic sinusitis with nasal polyps (CRSwNP). The investigators expect this study to provide convincing evidence that dupilumab improves clinical olfaction via direct reduction in olfactory cleft inflammation.

Interventions

  • DRUG Dupilumab

Study Locations (2)

South Carolina

  • Medical University of South Carolina - Charleston

Virginia

  • University of Virginia - Charlottesville

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2023-08-10
Est. Completion 2025-01-30
Phase Phase 4

What the Registry Record Tells You About NCT05964465

The ClinicalTrials.gov registry entry for NCT05964465 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 137-participant average among 11 other Chronic Rhinosinusitis With Nasal Polyps trials with a reported enrollment target (56% lower). The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Rhinosinusitis With Nasal Polyps appearing as the primary indexed condition, and to 1 intervention - of which Dupilumab is the first listed.

NCT05964465 reports 2 study locations spanning 2 distinct geographic areas - top geographies include South Carolina, Virginia.

Frequently Asked Questions

What is clinical trial NCT05964465 about?

NCT05964465 is a clinical study titled "Mechanisms of Smell Improvement With Dupilumab.". This study seeks to explore the mechanism through which dupilumab improves olfactory cleft inflammation in patients with chronic sinusitis with nasal polyps (CRSwNP). The investigators expect this study to provide convincing evidence that dupilumab improves clinical olfaction via direct reduction in...

What is the current status of trial NCT05964465?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2023-08-10. Estimated completion is 2025-01-30.

What conditions does trial NCT05964465 study?

This clinical trial studies the following conditions: Chronic Rhinosinusitis With Nasal Polyps.

What interventions are being tested in trial NCT05964465?

The interventions under investigation include: Dupilumab (DRUG).

Who is sponsoring clinical trial NCT05964465?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05964465 being conducted?

This trial has 2 study locations across South Carolina, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Rhinosinusitis With Nasal Polyps

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.